Precursor Cell Lymphoblastic Leukemia-Lymphoma: all 2,121 studies
Page 4 of 22. Open to participants first (492), then studies with results posted, then the rest; newest registration first within each.
- Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia.RecruitingNCT05950204Not applicable
- H19 in Acute Lymphoblastic Leukemia.Not yet recruitingNCT05943093
- InterNatIonal CHildhood Leukemia Microbiome/MEtabolome CohortRecruitingNCT05929976
- CAR T-cell Therapy in Patients With Renal DysfunctionRecruitingNCT05909059Phase 2
- Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological MalignanciesRecruitingNCT05887167Phase 1
- Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and LymphomaRecruitingNCT05873322
- Ex Vivo Drug Sensitivity Testing and Multi-Omics ProfilingRecruitingNCT05857969Phase 1
- TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia IIRecruitingNCT05848687Phase 1/2
- Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic LeukemiaRecruitingNCT05827549Phase 2
- Genetic Polymorphisms in Drug Induced Neuropathy in Children With ALLRecruitingNCT05811910
- Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALLRecruitingNCT05811845
- Determining the Mechanisms of Loss of CAR T Cell PersistenceRecruitingNCT05809284
- Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCTRecruitingNCT05809167Phase 2
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant DiseasesRecruitingNCT05800210Phase 2
- MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG DosingRecruitingNCT05794880Not applicable
- Study of the Medullary Microenvironment in Acute Childhood LeukemiaRecruitingNCT05792007Not applicable
- Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHLNot yet recruitingNCT05779930Early Phase 1
- Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelAvailableNCT05776134
- HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05751044Phase 1/2
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingNCT05748171Phase 2
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical ResearchRecruitingNCT05747157Early Phase 1
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic LymphomaRecruitingNCT05745181Phase 2
- Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic MalignanciesRecruitingNCT05739227Early Phase 1
- Expanded Access to ZiftomenibAvailableNCT05738538
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic LeukemiasRecruitingNCT05729178
- CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT05727683Phase 1
- Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid MalignanciesRecruitingNCT05705570Phase 1
- South China Children Cancer Group - Relapsed-Acute Lymphoblastic Leukemia 2022 ProtocolRecruitingNCT05682131Phase 4
- ThisCART19A Bridging to alloHSCT for R/R B-ALLRecruitingNCT05679687Phase 1
- VR-PAT During Home Burn Dressings - MultisiteEnrolling by invitationNCT05673551Not applicable
- Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaRecruitingNCT05660473Phase 2
- HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05658640Phase 1/2
- CAV Regimen for R/R Ph- B-ALLRecruitingNCT05657652Not applicable
- To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALLRecruitingNCT05651191Early Phase 1
- CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility ProtocolRecruitingNCT05648019Phase 2
- Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic LeukemiaRecruitingNCT05639673
- Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBLRecruitingNCT05626400Not applicable
- A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph...RecruitingNCT05621291Not applicable
- The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological MalignanciesRecruitingNCT05618041Not applicable
- Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBLRecruitingNCT05598593Phase 2
- CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic LeukemiaRecruitingNCT05596266Phase 1
- CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)RecruitingNCT05581030Phase 1
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)RecruitingNCT05579132Phase 1/2
- Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/LeukemiaRecruitingNCT05576532Phase 2
- Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT05576181Phase 1
- CD34+ Transplants for Myeloid MalignanciesNot yet recruitingNCT05565105Phase 2
- Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALLRecruitingNCT05559450Phase 2
- Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesRecruitingNCT05541341
- UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1RecruitingNCT05535855Phase 1
- Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic LeukemiaRecruitingNCT05519579Phase 2
- Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic LeukemiaRecruitingNCT05512169
- A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007Enrolling by invitationNCT05509855
- Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic LeukemiaRecruitingNCT05501899Early Phase 1
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
- Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell MalignanciesRecruitingNCT05487651Phase 1
- Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic MalignanciesRecruitingNCT05476770Phase 1
- Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia PatientsRecruitingNCT05452668Not applicable
- HIIT in Pediatric Heart Transplant Recipients (MedBIKE™)RecruitingNCT05451979Not applicable
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/2
- Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage LeukaemiaRecruitingNCT05429905Phase 1/2
- Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid MalignanciesRecruitingNCT05418088Phase 1
- Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)RecruitingNCT05397184Phase 1
- CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation TreatmentRecruitingNCT05381662Phase 1/2
- Safety and Efficacy Evaluation of Next-generation CD19-UCARTNot yet recruitingNCT05381181Phase 1
- Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALLRecruitingNCT05379569Phase 4
- European Prospective Investigation Into Childhood CancerRecruitingNCT05375617
- Bio-CAR-T BS StudyRecruitingNCT05366569
- Pediatric Orthopaedic Implant Safety & EfficacyRecruitingNCT05361980
- A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and AdolescentsRecruitingNCT05334823Phase 2
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruitingNCT05334069
- Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/LymphomaRecruitingNCT05333302Phase 1
- Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute LeukemiaRecruitingNCT05327894Phase 3
- The Patient Cohort of the National Center for Precision Medicine in LeukemiaRecruitingNCT05326919
- Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)RecruitingNCT05322850Phase 1/2
- Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of PersistenceRecruitingNCT05310591Phase 1/2
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT05309213Phase 1/2
- The Association of Gut Microbiota With COVID 19 Infection in ChildrenRecruitingNCT05303155
- Venetoclax Basket Trial for High Risk Hematologic MalignanciesRecruitingNCT05292664Phase 1
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- Residual Disease Driven Strategy for CARCIK (CD19) in Adults/Pediatric BCP-ALLRecruitingNCT05252403Phase 2
- Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic LeukemiaRecruitingNCT05210907Phase 1
- Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT SurvivorsRecruitingNCT05194397Phase 2
- RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALLRecruitingNCT05127148
- CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesRecruitingNCT05105867Early Phase 1
- Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLRecruitingNCT05082519Phase 2
- Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic LymphomaRecruitingNCT05075681Phase 1/2
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLNot yet recruitingNCT05054465Phase 1/2
- CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaRecruitingNCT05054257Phase 1
- CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic LeukaemiaRecruitingNCT05043571Phase 1
- ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.RecruitingNCT05038696Phase 1
- Two Step Haplo With Radiation ConditioningRecruitingNCT05031897Phase 2
- Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)RecruitingNCT05029531Phase 3
- Fitness and Lung Function Among Survivors of Heart Transplant, Leukemia and Infant BPD Through ExerciseRecruitingNCT05025774
- Backtracking Leukemia-Typical Somatic Mutations in Cord BloodRecruitingNCT05014165
- Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell TransplantationRecruitingNCT05005299Phase 1
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)RecruitingNCT04988555Phase 1/2
- Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic LeukemiaRecruitingNCT04977895